Bretaris Genuair
Bretaris Genuair Uses, Dosage, Side Effects, Food Interaction and all others data.
Bretaris Genuair is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Bretaris Genuair does not prolong the QTc interval or have significant effects on cardiac rhythm.
| Trade Name | Bretaris Genuair |
| Availability | Prescription only |
| Generic | Aclidinium |
| Aclidinium Other Names | Aclidinio |
| Related Drugs | Trelegy Ellipta, ProAir Digihaler, prednisone, Symbicort, Breo Ellipta, Ventolin, Xopenex, Ventolin HFA, Spiriva, Anoro Ellipta |
| Type | |
| Formula | C26H30NO4S2 |
| Weight | Average: 484.651 Monoisotopic: 484.161624833 |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Bretaris Genuair is an inhaled long-acting anticholinergic used as a maintenance bronchodilator in patients with chronic obstructive pulmonary disease (COPD).
Bretaris Genuair bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Bretaris Genuair is also used to associated treatment for these conditions: Chronic Obstructive Pulmonary Disease (COPD)
How Bretaris Genuair works
Bretaris Genuair is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Bretaris Genuair's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
Toxicity
Most common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.
Food Interaction
No interactions found.Bretaris Genuair Drug Interaction
Moderate: umeclidinium / vilanterol, ipratropium, albuterol / ipratropium, albuterol / ipratropiumUnknown: aspirin, fluticasone / salmeterol, mometasone, mometasone, aspirin, fluticasone / vilanterol, tamsulosin, nitroglycerin, acetaminophen, clopidogrel, albuterol, beclomethasone, budesonide / formoterol, acetaminophen, albuterol, cholecalciferol
Bretaris Genuair Disease Interaction
Major: milk protein allergiesModerate: liver impairment, anticholinergic effects
Volume of Distribution
Following IV administration, the volume of distribution is 300 L
Elimination Route
Bioavailability, healthy subjects = 6%; T max, healthy subjects = 10 minutes; Time to steady state, healthy subjects = 2 days;
Half Life
Plasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). Effective half-life = 5-8 hours.
Clearance
Total clearance, IV dose, young healthy subjects = 170 L/h (inter-individual variability of 36%)
Elimination Route
Intravenously administered radiolabelled aclidinium bromide was administered to healthy volunteers and was extensively metabolized with 1% excreted as unchanged aclidinium. Approximately 54% to 65% of the radioactivity was excreted in urine and 20% to 33% of the dose was excreted in feces. The combined results indicated that almost the entire aclidinium bromide dose was eliminated by hydrolysis. After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose.
Innovators Monograph
You find simplified version here Bretaris Genuair
